Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR115 in HER2-positive advanced solid malignancies
NCT06388902Phase 1Suspended
- Sponsor
- BioRay Pharmaceutical
- Start
- Feb 2024
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BR115 in malignant solid tumor, sponsored by BioRay Pharmaceutical. Primary endpoint: Treatment-emergent Adverse Events at 24 months. Started Feb 2024; status: suspended.
02
Drugs
BR115
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06388902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388902.